Baidu
map

Nature Genetics:HPV全基因组整合图谱分析

2015-01-20 何嫱 生物通

来自华中科技大学、南方医科大学、华大基因研究院等机构的研究人员,通过对宫颈癌(cervical cancer)进行全基因组人类乳头瘤病毒(HPV)整合图谱分析,鉴别出了一些成簇的基因组热点,并揭示出了由微同源(microhomology)介导的一种潜在整合机制。这些研究结果发表在1月12日的《自然遗传学》(Nature Genetics)杂志上。 华中科技大学的马丁(Ding Ma)教授、汪辉(

来自华中科技大学、南方医科大学、华大基因研究院等机构的研究人员,通过对宫颈癌(cervical cancer)进行全基因组人类乳头瘤病毒(HPV)整合图谱分析,鉴别出了一些成簇的基因组热点,并揭示出了由微同源(microhomology)介导的一种潜在整合机制。这些研究结果发表在1月12日的《自然遗传学》(Nature Genetics)杂志上。

华中科技大学的马丁(Ding Ma)教授、汪辉(Hui Wang)教授以及华大基因研究院副院长徐讯(Xun Xu)是这篇论文的共同通讯作者。

宫颈癌是女性生殖系统最常见的恶性肿瘤。在发展中国家,其发病率甚至超过乳腺癌,成为严重威胁妇女健康和生命的第一大恶性肿瘤。目前宫颈癌的治疗主要以手术和放疗为主,化疗和其他免疫治疗为辅,其五年生存率仅为55%左右。

流行病学研究显示,HPV在人体正常宫颈上皮细胞中持续感染是宫颈癌发生的主要诱因之一。人体在受到HPV感染后,免疫系统会尝试将其清除。如果此时病毒仍逗留在体内,就会插入人体基因组,最终导致癌症发生。因而,HPV整合入宿主基因组是宫颈癌发生和发展过程中的一个关键遗传事件,大约90%左右的宫颈癌中均可检测到HPV的整合。深入探索HPV导致宫颈癌发生的致病机理,并在此基础上开发靶向治疗新策略,一直是研究者关注的热点。

在这篇新文章中,研究人员通过采用全基因组测序和高通量病毒整合检测,在26个宫颈上皮内瘤变(cervical intraepithelial neoplasia)、104个宫颈癌和5个细胞系中鉴别出了3,667个HPV整合断点。除重新计算了以往发现的一些频繁整合位点:POU5F1B (9.7%)、 FHIT (8.7%)、KLF12 (7.8%)、KLF5 (6.8%)、LRP1B (5.8%)和LEPREL1 (4.9%)的整合频率外,研究人员还发现了一些新的热点:HMGA2 (7.8%), DLG2 (4.9%)及SEMA3D (4.9%)。

他们发现当HPV整合到FHIT和LRP1B基因的内含子中时,它们的蛋白质表达下调。而当HPV整合到MYC和HMGA2基因的侧翼区时,这些基因的蛋白质表达升高。此外,研究人员发现有一些人类基因组和HPV基因组的微同源序列显著富基于整合断点附近,表明有可能通过微同源介导的一些DNA修复信号通路,使得病毒和人类DNA之间发生了融合

这些研究数据提供了有关HPV整合驱动宫颈癌发生的一些新见解。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1733729, encodeId=96d41e33729c5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Feb 11 05:10:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685980, encodeId=aa741685980d1, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Mar 16 19:10:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880465, encodeId=50681880465fe, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 11 10:10:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877949, encodeId=8bea18e7949e3, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Aug 12 03:10:00 CST 2015, time=2015-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048638, encodeId=e2002048638e0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Mar 26 03:10:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546440, encodeId=4c5b1546440f3, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Jan 22 06:10:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]
    2015-02-11 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1733729, encodeId=96d41e33729c5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Feb 11 05:10:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685980, encodeId=aa741685980d1, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Mar 16 19:10:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880465, encodeId=50681880465fe, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 11 10:10:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877949, encodeId=8bea18e7949e3, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Aug 12 03:10:00 CST 2015, time=2015-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048638, encodeId=e2002048638e0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Mar 26 03:10:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546440, encodeId=4c5b1546440f3, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Jan 22 06:10:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1733729, encodeId=96d41e33729c5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Feb 11 05:10:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685980, encodeId=aa741685980d1, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Mar 16 19:10:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880465, encodeId=50681880465fe, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 11 10:10:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877949, encodeId=8bea18e7949e3, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Aug 12 03:10:00 CST 2015, time=2015-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048638, encodeId=e2002048638e0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Mar 26 03:10:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546440, encodeId=4c5b1546440f3, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Jan 22 06:10:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]
    2015-09-11 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1733729, encodeId=96d41e33729c5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Feb 11 05:10:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685980, encodeId=aa741685980d1, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Mar 16 19:10:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880465, encodeId=50681880465fe, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 11 10:10:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877949, encodeId=8bea18e7949e3, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Aug 12 03:10:00 CST 2015, time=2015-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048638, encodeId=e2002048638e0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Mar 26 03:10:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546440, encodeId=4c5b1546440f3, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Jan 22 06:10:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]
    2015-08-12 huperzia
  5. [GetPortalCommentsPageByObjectIdResponse(id=1733729, encodeId=96d41e33729c5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Feb 11 05:10:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685980, encodeId=aa741685980d1, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Mar 16 19:10:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880465, encodeId=50681880465fe, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 11 10:10:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877949, encodeId=8bea18e7949e3, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Aug 12 03:10:00 CST 2015, time=2015-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048638, encodeId=e2002048638e0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Mar 26 03:10:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546440, encodeId=4c5b1546440f3, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Jan 22 06:10:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]
    2015-03-26 cy0324
  6. [GetPortalCommentsPageByObjectIdResponse(id=1733729, encodeId=96d41e33729c5, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Feb 11 05:10:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685980, encodeId=aa741685980d1, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Mon Mar 16 19:10:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880465, encodeId=50681880465fe, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 11 10:10:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877949, encodeId=8bea18e7949e3, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Wed Aug 12 03:10:00 CST 2015, time=2015-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048638, encodeId=e2002048638e0, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Thu Mar 26 03:10:00 CST 2015, time=2015-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546440, encodeId=4c5b1546440f3, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Jan 22 06:10:00 CST 2015, time=2015-01-22, status=1, ipAttribution=)]

相关资讯

抗艾滋病药物洛匹那韦能有效抑制HPV病毒,防治宫颈癌

一项在肯尼亚进行的临床试验显示,治疗艾滋病的常用药物洛匹那韦对于人乳头瘤病毒(HPV)导致的宫颈病变具有良好疗效,能够防止其发展成宫颈癌。 此间媒体近日报道说,这项试验是肯尼亚肯雅塔国家医院和英国曼彻斯特大学联合进行的。40名因感染HPV而发生宫颈癌前病变的女性参与试验,她们将洛匹那韦作为宫颈栓剂使用,连续用药两周。 试验开始时,40名患者都患有不同程度的宫颈癌前病变,其中23名为高度病变,3个月

WCC 2014:关注性问题:把性健康纳入癌症管理工作的一部分

这次会议的专家小组成员确实是来自五湖四海,他们为证明性健康的重要性和理解人类性生活和亲密行为在有效治疗非性疾病中作用为集聚在一起。在小组会议的开始,Dr Woet Gianotten详细介绍了性生活可带给身体的好处如提高睡眠质量、增加互信和提高关系质量、缓解疼痛以及延长寿命。小组专家认为,除了一些因素是与每个人的生活方式具有内在关联性外,不考虑患者性生活而进行的诊断和治疗最终都

包皮环切术可减少HPV负荷量

Nature Reviews Urology近日刊文报道,包皮环切术可以减少高危型人乳头瘤病毒(HPV)的负荷量。 高危型人乳头瘤病毒如HPV16和HPV18可以导致阴茎癌和宫颈癌;男性高病毒负荷量的HPV感染可以增加女性性伴侣病毒感染的机会。以前的研究表明男性包皮环切可以减少高危型HPV感染,但是没有探讨包皮环切对阴茎病毒负荷量的影响。 来自肯尼亚的研究者在2

郎景和:16+18=85,两种HPV病毒导致八成宫颈癌

对于数学运算来说,“16+18=85”显然是错误的,但对于所有女性来说,这个计算式却非常重要。此间提示了三个非常重要的信息,即我国超过85%的宫颈癌都是由“HPV16”和“HPV18”引起的。 宫颈癌是世界第三大常见女性癌症。全球每年有将近50万名女性被诊断为宫颈癌,死亡率高达50%,且主要发生在亚洲。研究证实,99%的宫颈癌病例都是由人乳头状瘤病毒(HPV)导致的。大部分HPV感染都没有症状,能

宫颈癌疫苗:国内为何独缺席

   虽然在很多国家,宫颈癌疫苗已经上市,但在中国,生产宫颈癌疫苗的公司依旧很难获得市场“通行证”。(CFP/图) 八年前,世界上第一支可以预防癌症的疫苗——HPV疫苗上市;七年前,疫苗开始了中国内地的上市之路;现在,在内地,因为新药审评标准存在争议,它依然是被禁止的。 中国每年约有8万女性因宫颈癌去世,约有15万新增病例。而学者研究显示,2006-2012年间,因为9到15岁的女孩未能

Vaccine:新措施有效改善青少年HPV疫苗接种率的

一般来讲,改变医生的行医方式是很困难的,近日,一项刊登于国际杂志Vaccine上的研究论文中,来自波士顿大学医学中心的研究人员通过研究表示,将质量改进及激励措施同传统的教育相结合或许可以改善男孩儿和女孩儿的人乳头瘤病毒(HPV)疫苗的接种率,该研究或为持续性改善HPV疫苗的接种率提供帮助。 每年大约有300万美国人寻找治疗HPV相关疾病的疗法,2.7万美国人都患有HPV相关的癌症,而5000多

Baidu
map
Baidu
map
Baidu
map